OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2016.5345 OL-0-0-5345 Articles Combining fisetin and ionizing radiation suppresses the growth of mammalian colorectal cancers in xenograft tumor models LeuJyh-Der 1 * WangBo-Shen 2 * ChiuShu-Jun 3 ChangChun-Yuan 2 ChenChien-Chih 4 ChenFu-Du 5 AvirmedShiirevnyamba 6 LeeYi-Jang 2 7 Department of Radiation Oncology, Taipei City Hospital, Renai Branch, Da'an, Taipei 106, Taiwan, R.O.C. Department of Biomedical Imaging and Radiological Sciences, School of Biomedical Engineering, National Yang-Ming University, Beitou, Taipei 112, Taiwan, R.O.C. Department of Life Sciences, Tzu Chi University, Hualien 970, Taiwan, R.O.C. Department of Family Medicine, Taipei City Hospital, Renai Branch, Da'an, Taipei 112, Taiwan, R.O.C. Department of Electronic Engineering, Hwa-Hsia University of Technology, Zhonghe, Taipei 235, Taiwan, R.O.C. Department of Surgery, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia Biophotonics & Molecular Imaging Research Center, National Yang-Ming University, Beitou, Taipei 112, Taiwan, R.O.C. Correspondence to: Professor Yi-Jang Lee, Department of Biomedical Imaging and Radiological Sciences, School of Biomedical Engineering, National Yang-Ming University, 155, Section 2, Linong Street, Beitou, Taipei 112, Taiwan, R.O.C., E-mail: yjlee2@ym.edu.tw

Contributed equally

 12 2016 02 11 2016 12 6 4975 4982 19072015 12092016 Copyright: © Leu et al. 2016 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Fisetin (3,7,3′,4′-tetrahydroxyflavone), which belongs to the flavonoid group of polyphenols and is found in a wide range of plants, has been reported to exhibit a number of biological activities in human cancer cells, including antioxidant, anti-inflammatory, antiangiogenic, anti-invasive and antiproliferative effects. Although previous in vitro studies have shown that fisetin treatment increases the apoptotic rate and enhances the radiosensitivity of human colorectal cancer cells, the in vivo effects of fisetin on tumor growth remain unclear. In the present study a murine xenograft tumor model was employed to investigate the therapeutic effects of fisetin in combination with radiation on CT-26 colon cancer cells and human HCT116 colorectal cancer cells. This revealed that intratumoral injection of fisetin significantly suppressed the growth of CT-26 tumors compared with the untreated control group, but had little effect on the growth of HCT116 tumors. However, fisetin in combination with 2-Gy radiation enhanced tumor suppressor activity in murine colon and human colorectal xenograft tumors, as compared with 2-Gy fractionated radiation administered alone for 5 days and fisetin alone. Interestingly, fisetin downregulated the expression of the oncoprotein securin in a p53-independent manner. However, securin-null HCT116 tumors showed only moderate sensitivity to fisetin treatment, and the combination of fisetin and radiation did not significantly suppress securin-null HCT116 tumor growth compared with normal HCT116 tumors. Therefore, the role of securin in mediating the effect of fisetin on colorectal cancer growth warrants further investigation. In conclusion, the results of the current study provide important preclinical data for evaluating the efficacy of fisetin and radiation combination treatment as an adjuvant chemoradiotherapy for human colorectal cancers.

 fisetin colorectal cancer radiotherapy xenograft tumor model securin Introduction

Colorectal cancer is the third leading cause of mortality in the Western world (1) and has emerged as a common malignancy in the Asian population as a result of changes in diet and physical activity levels (2). Dietary habits have been related to the risk of colorectal cancer (3,4). Surgery and chemotherapy are the primary treatments for colorectal cancer. Radiotherapy is a typical adjuvant treatment after surgery or chemotherapy for high-stage colorectal cancers (5,6). However, colorectal carcinomas display a wide range of radiosensitivity (7,8). Therefore, new approaches are necessary to enhance the efficacy of radiation treatments for colorectal cancers.

Previous epidemiological studies have shown that the daily inclusion of fruit and vegetables in the diet decreases the risk of colon cancer (9). In addition, it has been reported that flavonoids, which are abundant in numerous plants, protect against a number of tumorigenic processes, including oxidative stress, inflammation, angiogenesis and cell invasion (10–12). Furthermore, flavonoids induce cell cycle arrest, apoptosis and radiosensitivity in cancer cells in vitro (13–15). The flavonoid fisetin (3,7,3′,4′-tetrahydroxyflavone) is a polyphenol found in numerous plants. A number of previous reports have shown that fisetin activates p53 activity, and represses the cyclooxygenase-2 and Wnt/epidermal growth factor receptor/nuclear factor-B signaling pathways in human cancer cells to promote apoptosis (14,16–18). In addition, fisetin inhibits the spindle checkpoint response that arrests cells in the radiosensitive G2/M phase (19,20). However, the in vivo effects of fisetin remain unclear. As fisetin is a natural and edible product with acceptable biosafety, the clinical potential of this compound is of particular interest and warrants further investigation.

Securin, which was originally isolated from rat pituitary tumor cells, is alternatively called the pituitary tumor transforming gene (21). Securin is a multi-functional protein that serves a number of biological roles, such as the regulation of cellular transformation, sister chromatid separation (22,23), gene transcription (24) and DNA damage repair (25,26). Notably, securin interacts with p53 and perturbs p53-mediated transcription and apoptosis in tumor cells (22). Thus, securin is regarded as an oncoprotein. The depletion of securin has been reported to sensitize human colorectal cancer cells to various types of treatment, including fisetin, butein and ionizing radiation (27–29). However, whether these effects can be repeated in vivo is unknown.

In the present study, tumor-bearing mice were used to examine the effect of fisetin alone and in combination with radiation on the growth of colorectal tumors in vivo. In addition, tumors with defective securin expression were assessed to investigate if securin depletion would enhance sensitivity to these treatments.

 Materials and methods <sec> <title>Cell culture

Murine CT-26 colon cancer cells, and human HCT116WT, HCT116p53-/−, HCT116securin-/− and p53-R273H mutant HT-29 colorectal cancer cell lines (30) were cultured in RPMI-1640 medium (Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (Thermo Fisher Scientific Inc.), 100 U/ml penicillin, 100 µg/ml streptomycin and 1 mM sodium pyruvate. Cultures were maintained at 37°C in a 95% humidified incubator (Thermo Fisher Scientific, Inc.) with 5% CO2 and passaged at 1:3 every 2 days.

 Mouse xenograft models

A total of 62 male BALB/c nude mice (weight, 20 g; age, 6 weeks) were purchased from the National Laboratory Animal Center (NLAC, Nankang, Taipei, Taiwan). The mice were maintained at 22–24°C and 70% humidity under a 12-h light/dark cycle. Food and water were available ad libitum. Five mice were kept in each 77.4×77.4-cm cage. All animal protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of National Yang-Ming University (Taipei, Taiwan; approval no. 1001270). Prior to tumor xenografting, mice were anesthetized with ketamine (50 mg/kg; IMALGENE®; Merial Laboratoire de Toulouse, Lyon, France) and xylazine (15 mg/kg; Sigma-Aldrich; Merck Millipore, Darmstadt, Germany). Subsequently, CT-26 (1×106) or HCT116 (2×106) cells were subcutaneously injected into the hind legs of the mice (n=5 for injection of each cell line). Prior to further treatment, mice were maintained until tumors reached 100 mm3. Tumor volume was measured using a caliper and calculated as the following: (Length × width2) / 2. Tumor volume was measured every 2–3 days to draw tumor growth curves followed by measurement of body weight.

 Reagents and radiation treatments

Fisetin was purchased from Sigma-Aldrich (Sigma-Aldrich) and intratumorally injected at a dose of 5 mg/kg on days 0 and 7. Tumors were irradiated with 2 Gy/day for 5 days using an X-ray machine (RS 2000 Biological Research X-ray Irradiator; Rad Source Technologies, Inc., Suwanee, GA, USA) operating at 160 kVp and 25 mA. The dose rate at a source to subject distance of 38 cm was 1.83 Gy/min. For combined fisetin and radiation treatment, mice were treated with 5 mg/kg fisetin followed by 2 Gy irradiation on days 0 and 7. For the control group, the mice were injected with DMSO at the same volume of dissolved fisetin on days 0 and 7. Five mice were used in each group. These treatments are illustrated on a timeline in Fig. 1. Excluding the tumor site, all areas of the mice were masked using a lead radiation protector.

 Western blotting and antibodies

Western blot analysis was performed as described previously (29). The following primary antibodies were used: Anti-p53 (Cat. no. GEX70214; 1:2,000; GeneTex, Inc., Irvine, CA, USA), anti-securin (Cat. no. ab3305; 1:1,000; Abcam, Cambridge, UK) and anti-GAPDH (Cat. no. PB197650; 1:5,000; Thermo Fisher Scientific Inc.). The secondary antibodies included a goat anti-mouse antibody (Cat. no. AP124P; 1:10,000; EMD Millipore, Billerica, MA, USA) for detecting the anti-securin and anti-GAPDH primary antibodies, and a goat anti-rabbit antibody (Cat. no. AP132P; 1:10,000; EMD Millipore) for detecting the anti-p53 primary antibody. Band intensities were measured by densitometry using ImageJ 1.x software (National Institutes of Health, Bethesda, MD, USA) (31).

 Cell proliferation measurement

Cells (1×105) were seeded into 6-cm culture dishes and collected for hemocytometric calculation every day for 7 days. For each time point, the mean number of cells was calculated from three independent cell cultures. The results were plotted as cell proliferation curves.

 Statistical analysis

Results are presented as the mean ± standard deviation. A Student's t-test was performed to determine if differences between groups were statistically significant. For survival analysis, the Kaplan-Meier estimator was used and the results were analyzed using the log-rank test. Statistical analyses were performed using GraphPad Prism 3.0 software (GraphPad Software, Inc., La Jolla, CA, USA). P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Fisetin inhibits tumor growth in a mouse CT-26 xenograft model

To examine the effect of fisetin on colorectal cancer growth in vivo, a mouse tumor xenograft model generated by injection of CT-26 colon cancer cells was treated with fisetin. Compared with the untreated control group, a single intratumoral injection of 5 mg/kg fisetin significantly reduced tumor volume for the following 10 days (Fig. 2A). As tumors appeared to re-grow 6 days after the first injection, a second dose of fisetin was administered on day 11 to examine if tumor growth could be inhibited. The results demonstrated that tumor growth was significantly suppressed for 3 days following the second administration of fisetin, as compared with the control group (Fig. 2A), although tumor growth was not completely inhibited. Fluctuations in body weight between the control and fisetin-treated group were similar (Fig. 2B), indicating that the concentration of fisetin used in this study was not cytotoxic. In addition, the survival rate of fisetin-treated tumor-bearing mice was increased compared with the untreated control group (Fig. 2C). These results demonstrate that administration of fisetin suppresses in vivo tumor growth in a mouse CT-26 xenograft model.

 Combining fisetin and radiation for the treatment of mammalian colorectal cancers

Treatment with a combination of fisetin and radiation treatment was investigated in mouse CT-26 and HCT116WT xenograft tumor models. The timeline of fisetin and radiation treatment is illustrated in Fig. 1; 2-Gy X-rays were administered to the tumor site five times between the first and second fisetin treatments to mimic a clinical regime. The results showed that CT-26 tumor growth was suppressed by fisetin and radiation alone; however, this effect was enhanced by combining the two treatments at 16 to 29 days following treatment (Fig. 3A). Body weight was not significantly different between any of the groups, suggesting that combined fisetin/radiation treatment did not cause systemic toxicity (Fig. 3B). In addition, HCT116 tumor growth was completely and significantly inhibited by combined fisetin/radiation treatment (P<0.05 vs. the control group; Fig. 3C), without significant loss of body weight (Fig. 3D). These results suggest that combined fisetin and radiation treatment is highly effective in suppressing colorectal cancer.

 Fisetin induces p53 and suppresses securin protein expression in human colorectal cancer cells

p53 is a tumor suppressor protein that is regulated by a number of different proteins. A previous study demonstrated that the securin oncoprotein binds to p53 and modulates its activity (32). Although securin protein levels have been reported to be elevated by radiation independently of p53 activity (27), it is unknown whether fisetin influences the expression of p53 or securin. In the present study, an experiment with a series of fisetin doses was performed to investigate whether fisetin influences the expression of p53 and securin in different human colorectal cancer cell lines. The results identified that in HCT116WT cells, p53 protein levels were increased and securin protein levels were decreased following fisetin treatment (Fig. 4A). Interestingly, fisetin increased the expression of p53 in HCT116securin-/− cells and decreased the expression of securin in HCT116p53-/− cells (Fig. 4A). In p53 mutant HT-29 cells, fisetin downregulated the expression of securin protein (Fig. 4A). Quantification of the protein bands on the Western Blot analysis revealed the same results (Fig. 4B). These results indicate that fisetin increases the expression of p53 and decreases the expression of securin, which suppresses tumor growth. Furthermore, fisetin-mediated expression of p53 and securin was independent of the expressive status of p53/securin (null or wild-type).

 Effect of fisetin and radiation combination treatment on securin-null colorectal cell-formed xenograft tumors

As fisetin could induce the expression of the p53 protein in the absence of securin, the ability of fisetin and radiation treatment to suppress tumor growth in vivo was investigated. Firstly, the growth curves of HCT116WT and HCT116securin-/− cells were compared, which showed that the proliferation of HCT116securin-/− cells was significantly slower than that of HCT116WT cells after 3 days of proliferation (Fig. 5A). Tumor growth was moderately suppressed by fisetin treatment in HCT116securin-/− cells; however, no significant advantage was observed following fisetin and radiation combination treatment (Fig. 5B). The body weight of the mice following fisetin, radiation and fisetin/radiation showed no significant difference compared with the control group (Fig. 5C). Therefore, depletion of securin does not enhance the effects of fisetin and radiation combination treatment on colorectal tumors in vivo. However, a larger sample size is necessary to validate this result.

 Discussion

Previous studies have shown that fisetin possesses a wide range of activities to suppress the growth of human cancer cells, including breast, prostate, bladder, lung, melanoma and colorectal cancer cells (16,33–39). Among these types of cancer, colorectal cancer is particularly interesting with regards to fisetin, since fisetin is a nutrient supplement that can be administrated orally (40). It is thought that fisetin is absorbed through the digestive tract without the need for intravascular injection (41). Although in vitro studies have demonstrated the efficacy of fisetin in the treatment of colorectal cancer (15,16), few in vivo studies have been reported. Since preclinical studies are essential for potent therapeutic agents to be accepted for clinical trials, the experimental animal data in the present study is important for evaluating the application of fisetin to colorectal cancer therapy. In addition, the current study investigated whether fisetin treatment combined with ionizing radiation exerted synergistic effects. A previous study reported that a combination of cisplatin and fisetin exerted anticancer activity in embryonic carcinoma cells in vitro and in vivo (42). Although radiotherapy is not typically used in the treatment of colorectal cancer, it is frequently applied to adjuvant chemotherapy in rectal cancer (43,44). The combination of fisetin and radiotherapy is an interesting alternative adjuvant therapy, since it would likely avoid the side effects associated with chemotherapy.

In the present study, a mouse xenograft model was used to examine the tumor-suppressive efficacy of fisetin in vivo on colon and colorectal cancers. Animal (CT-26) and human (HCT116) colon and colorectal cancer cells, respectively, were used to establish xenograft tumor models. Fisetin treatment was shown to suppress the growth of tumors formed by CT-26 cells, but not HCT116 cells. However, treatment with fisetin combined with radiation exhibited enhanced tumor suppressive effects on CT-26 and HCT116 xenograft tumors. This finding supports the potential application of fisetin to adjuvant radiotherapy for colorectal cancers. As fisetin did not exert toxicity in the current study, or in other reports (45,46), its use as an adjuvant treatment should be feasible.

In the present study, CT-26 and HCT116 cell lines, which express wild-type p53, formed tumors that were sensitive to radiation treatment. Since p53 is known to be upregulated by radiation (47), it is reasonable that this phenomenon was observed in vivo in the present study. Importantly, the current study used clinically comparable fractionated radiation of 2-Gy/day/fraction for 5 days (48). Compared with this regime, the fisetin-combined radiation treatments only irradiated tumors at 2 Gy twice in one week, yet remained more efficient than the fractionated radiation on tumor suppression, suggesting that fisetin enhances the tumor response to radiation in vivo. Thus, the use of fisetin in adjuvant radiotherapy may reduce total radiation exposure and improve the quality of life of patients during and following treatment. Further investigations into the optimal combination for colorectal cancer therapy are warranted.

The genetic background of a tumor is known to influence the prognosis (49,50). The authors of the present study were interested in p53 and securin because of the results of our previous studies (15,27). Briefly, fisetin was shown to enhance the radiosensitivity of p53-mutant human HT-29 colorectal cancer cells, and promote apoptosis in securin-depleted human HCT-116 colorectal cancer cells. Consistent with a previous report (14), in the present study, we also showed that fisetin could induce p53 protein expression in wild-type and securin-null HCT116 cells. Furthermore, expression of the securin protein was downregulated by fisetin regardless of the p53 expression status. In addition, in the current study xenograft securin-null colorectal tumors exhibited increased sensitivity to fisetin compared with the untreated control. However, individual variance in the tumor-bearing mice may have reduced the extent of tumor suppression resulting from fisetin treatment. Therefore, an increased sample size is required to validate the effect of fisetin on securin-null colorectal cancers. In addition, this limitation should be considered for the investigation of fisetin and radiation combination treatment. In the current study, p53 protein expression was still induced in securin-null HCT116 cells by fisetin, indicating that p53 and securin protein expression should be modulated by fisetin and radiation combination treatment in order to achieve optimal tumor suppression.

In conclusion, the present study used mouse xenograft tumor models to investigate the effect of fisetin alone or in combination with radiation on colon and colorectal tumor growth. The results showed that fisetin treatment alone was sufficient to suppress murine CT-26 colon tumors, but not human HCT116 colorectal tumors. Interestingly, a combination of fisetin and radiation treatment enhanced the tumor suppression compared with fractionated irradiation alone. In addition, the results of the current study revealed that securin-null HCT116 tumors exhibited increased sensitivity to fisetin treatment, although this observation needs to be validated in a larger sample set. Investigating whether securin is the key molecule in mediating the effects of fisetin and radiation combination treatment on colon and colorectal cancers warrants future exploration. To the best of our knowledge, this is the first report demonstrating the therapeutic efficacy of fisetin and radiation combination treatment on colon and colorectal cancer in vivo. The results of the present study provide important preclinical information for evaluating the potential use of fisetin in adjuvant cancer radiotherapy.

 Acknowledgements

The present study was supported by the Taipei City Government Department of Health (Taipei, Taiwan; grant no. 10101-62-034) and the Ministry of Science and Technology (Taipei, Taiwan; grant nos. 102-2628-B-010-012-MY3 and 105-2628-B-010-013-MY3).

 References SiegelRDesantisCJemalAColorectal cancer statistics, 2014CA Cancer J Clin64104117201410.3322/caac.2122024639052 DaviesNJBatehupLThomasRThe role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: A review of the literatureBr J Cancer105(Suppl 1)S52S73201110.1038/bjc.2011.42322048034 DollRPetoRThe causes of cancer: Quantitative estimates of avoidable risks of cancer in the United States todayJ Natl Cancer Inst661191130819817017215 LinJZhangSMCookNRRexrodeKMLiuSMansonJELeeIMBuringJEDietary intakes of fruit, vegetables, and fiber, and risk of colorectal cancer in a prospective cohort of women (United States)Cancer Causes Control16225233200510.1007/s10552-004-4025-115947874 HamayaYGuarinosCTseng-RogenskiSSIwaizumiMDasRJoverRCastellsALlorXAndreuMCarethersJMEfficacy of Adjuvant 5-Fluorouracil Therapy for Patients with EMAST-Positive Stage II/III Colorectal CancerPLoS One10e0127591201510.1371/journal.pone.012759125996601 SaltzLBMinskyBAdjuvant therapy of cancers of the colon and rectumSurg Clin North Am8210351058200210.1016/S0039-6109(02)00041-512507208 AllalASKähneTReverdinAKLippertHSchlegelWReymondMARadioresistance-related proteins in rectal cancerProteomics422612269200410.1002/pmic.20030085415274120 MaWYuJQiXLiangLZhangYDingYLinXLiGDingYRadiation-induced microRNA-622 causes radioresistance in colorectal cancer cells by down-regulating RbOncotarget61598415994201510.18632/oncotarget.376225961730 LockKPomerleauJCauserLAltmannDRMcKeeMThe global burden of disease attributable to low consumption of fruit and vegetables: Implications for the global strategy on dietBull World Health Organ83100108200515744402 Martinez-PerezCWardCCookGMullenPMcPhailDHarrisonDJLangdonSPNovel flavonoids as anti-cancer agents: Mechanisms of action and promise for their potential application in breast cancerBiochem Soc Trans4210171023201410.1042/BST2014007325109996 OrlikovaBMenezesJCJiSKamatSPCavaleiroJADiederichMMethylenedioxy flavonoids: Assessment of cytotoxic and anti-cancer potential in human leukemia cellsEur J Med Chem84173180201410.1016/j.ejmech.2014.07.00325016375 ImaiMKikuchiHDendaTOhyamaKHirobeCToyodaHCytotoxic effects of flavonoids against a human colon cancer derived cell line, COLO 201: A potential natural anti-cancer substanceCancer Lett2767480200910.1016/j.canlet.2008.10.03619070422 LuXJungJIChoHJLimDYLeeHSChunHSKwonDYParkJHFisetin inhibits the activities of cyclin-dependent kinases leading to cell cycle arrest in HT-29 human colon cancer cellsJ Nutr13528842890200516317137 LimDYParkJHInduction of p53 contributes to apoptosis of HCT-116 human colon cancer cells induced by the dietary compound fisetinAm J Physiol Gastrointest Liver Physiol296G1060G1068200910.1152/ajpgi.90490.200819264955 ChenWSLeeYJYuYCHsaioCHYenJHYuSHTsaiYJChiuSJEnhancement of p53-mutant human colorectal cancer cells radiosensitivity by flavonoid fisetinInt J Radiat Oncol Biol Phys7715271535201010.1016/j.ijrobp.2010.02.04320637980 SuhYAfaqFJohnsonJJMukhtarHA plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-kappaB-signaling pathwaysCarcinogenesis30300307200910.1093/carcin/bgn26919037088 LiJChengYQuWSunYWangZWangHTianBFisetin, a dietary flavonoid, induces cell cycle arrest and apoptosis through activation of p53 and inhibition of NF-kappa B pathways in bladder cancer cellsBasic Clin Pharmacol Toxicol1088493201110.1111/j.1742-7843.2010.00613.x21054790 ChouRHHsiehSCYuYLHuangMHHuangYCHsiehYHFisetin inhibits migration and invasion of human cervical cancer cells by down-regulating urokinase plasminogen activator expression through suppressing the p38 MAPK-dependent NF-κB signaling pathwayPloS one8e71983201310.1371/journal.pone.007198323940799 SalmelaALPouwelsJVarisAKukkonenAMToivonenPHalonenPKPeräläMKallioniemiOGorbskyGJKallioMJDietary flavonoid fisetin induces a forced exit from mitosis by targeting the mitotic spindle checkpointCarcinogenesis3010321040200910.1093/carcin/bgp10119395653 HaddadAQVenkateswaranVViswanathanLTeahanSJFleshnerNEKlotzLHNovel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell linesProstate Cancer Prostatic Dis96876200610.1038/sj.pcan.450084516314891 PeiLMelmedSIsolation and characterization of a pituitary tumor-transforming gene (PTTG)Mol Endocrinol11433441199710.1210/mend.11.4.99119092795 RustgiAKSecurin a new role for itselfNat Genet32222224200210.1038/ng1002-22212355078 ZouHMcGarryTJBernalTKirschnerMWIdentification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesisScience285418422199910.1126/science.285.5426.41810411507 TongYEiglerTTranscriptional targets for pituitary tumor-transforming gene-1J Mol Endocrinol43179185200910.1677/JME-08-017619433493 KimDSFranklynJASmithVEStratfordALPembertonHNWarfieldAWatkinsonJCIshmailTWakelamMJMcCabeCJSecurin induces genetic instability in colorectal cancer by inhibiting double-stranded DNA repair activityCarcinogenesis28749759200710.1093/carcin/bgl20217071631 NagaoKAdachiYYanagidaMSeparase-mediated cleavage of cohesin at interphase is required for DNA repairNature43010441048200410.1038/nature0280315329725 YuSHYangPMPengCWYuYCChiuSJSecurin depletion sensitizes human colon cancer cells to fisetin-induced apoptosisCancer Lett30096104201110.1016/j.canlet.2010.09.01520974518 HuangYTLinCIChienPHTangTTLinJChaoJIThe depletion of securin enhances butein-induced apoptosis and tumor inhibition in human colorectal cancerChem Biol Interact2204150201410.1016/j.cbi.2014.06.00624931875 ChenWSYuYCLeeYJChenJHHsuHYChiuSJDepletion of securin induces senescence after irradiation and enhances radiosensitivity in human cancer cells regardless of functional p53 expressionInt J Radiat Oncol Biol Phys77566574201010.1016/j.ijrobp.2009.12.01320457353 HauptSdi AgostinoSMizrahiIAlsheich-BartokOVoorhoeveMDamalasABlandinoGHauptYPromyelocytic leukemia protein is required for gain of function by mutant p53Cancer Res6948184826200910.1158/0008-5472.CAN-08-401019487292 SchneiderCARasbandWSEliceiriKWNIH Image to ImageJ: 25 years of image analysisNat Methods9671675201210.1038/nmeth.208922930834 BernalJALunaREspinaALázaroIRamos-MoralesFRomeroFAriasCSilvaATortoleroMPintor-ToroJAHuman securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosisNat Genet32306311200210.1038/ng99712355087 YangPMTsengHHPengCWChenWSChiuSJDietary flavonoid fisetin targets caspase-3-deficient human breast cancer MCF-7 cells by induction of caspase-7-associated apoptosis and inhibition of autophagyInt J Oncol40469478201221922137 KhanNAfaqFSyedDNMukhtarHFisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LNCaP cellsCarcinogenesis2910491056200810.1093/carcin/bgn07818359761 LiJQuWChengYSunYJiangYZouTWangZXuYZhaoHThe inhibitory effect of intravesical fisetin against bladder cancer by induction of p53 and down-regulation of NF-kappa B pathways in a rat bladder carcinogenesis modelBasic Clin Pharmacol Toxicol115321329201410.1111/bcpt.1222924646039 KangKAPiaoMJHyunJWFisetin induces apoptosis in human nonsmall lung cancer cells via a mitochondria-mediated pathwayIn Vitro Cell Dev Biol Anim51300309201510.1007/s11626-014-9830-625381036 SyedDNChamcheuJCKhanMISechiMLallRKAdhamiVMMukhtarHFisetin inhibits human melanoma cell growth through direct binding to p70S6K and mTOR: Findings from 3-D melanoma skin equivalents and computational modelingBiochem Pharmacol89349360201410.1016/j.bcp.2014.03.00724675012 PalHCSharmaSStricklandLRKatiyarSKBallestasMEAtharMElmetsCAAfaqFFisetin inhibits human melanoma cell invasion through promotion of mesenchymal to epithelial transition and by targeting MAPK and NFκB signaling pathwaysPloS one9e86338201410.1371/journal.pone.008633824466036 SzliszkaEHelewskiKJMizgalaEKrolWThe dietary flavonol fisetin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cellsInt J Oncol39771779201121743964 KhanNSyedDNAhmadNMukhtarHFisetin: A dietary antioxidant for health promotionAntioxid Redox Signal19151162201310.1089/ars.2012.490123121441 SahuBDKumarJMSistlaRFisetin, a dietary flavonoid, ameliorates experimental colitis in mice: Relevance of NF-κB signalingJ Nutr Biochem28171182201610.1016/j.jnutbio.2015.10.00426878795 TripathiRSamadderTGuptaSSuroliaAShahaCAnticancer activity of a combination of cisplatin and fisetin in embryonal carcinoma cells and xenograft tumorsMol Cancer Ther10255268201110.1158/1535-7163.MCT-10-060621216935 BreugomAJvan GijnWMullerEWBerglundÅvan den BroekCBFokstuenTGelderblomHKapiteijnELeerJWMarijnenCAAdjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: A dutch colorectal cancer group (DCCG) randomized phase III trialAnn Oncol26696701201510.1093/annonc/mdu56025480874 Colorectal Cancer Collaborative GroupAdjuvant radiotherapy for rectal cancer: A systematic overview of 8,507 patients from 22 randomised trialsLancet35812911304200110.1016/S0140-6736(01)06409-111684209 CurraisAPriorMDarguschRArmandoAEhrenJSchubertDQuehenbergerOMaherPModulation of p25 and inflammatory pathways by fisetin maintains cognitive function in Alzheimer's disease transgenic miceAging Cell13379390201410.1111/acel.1218524341874 da CostaMPBozinisMCAndradeWMCostaCRda SilvaALde OliveiraCM AlvesKatoLOdeF FernandesSouzaLKMdoR SilvaAntifungal and cytotoxicity activities of the fresh xylem sap of Hymenaea courbaril L. and its major constituent fisetinBMC Complement Altern Med14245201410.1186/1472-6882-14-24525027026 FeiPEl-DeiryWSP53 and radiation responsesOncogene2257745783200310.1038/sj.onc.120667712947385 FertilBMalaiseEPInherent cellular radiosensitivity as a basic concept for human tumor radiotherapyInt J Radiat Oncol Biol Phys7621629198110.1016/0360-3016(81)90377-17275727 LindströmLSHallPHartmanMWiklundFCzeneKIs genetic background important in lung cancer survival?PloS one4e5588200910.1371/journal.pone.000558819478952 AshworthALordCJReis-FilhoJSGenetic interactions in cancer progression and treatmentCell1453038201110.1016/j.cell.2011.03.02021458666

Timeline of treatments of tumor-bearing mice (n=5 per group). Treatments began when tumor volume reached 100 mm3.

Effect of fisetin on CT-26 colorectal tumors in vivo. (A) Tumor growth curves of tumor-bearing mice with or without intratumoral injection of fisetin (n=5 for each group). *P<0.05. (B) Body weights of mice following measurement of tumor size. Arrows represent when fisetin injections occurred. (C) Kaplan-Meier estimator survival curves for tumor-bearing mice with or without intratumoral injection of fisetin.

Effect of fisetin and radiation combination treatment on colorectal tumor growth in vivo. (A) Growth curves for CT-26 xenograft tumors. (B) Body weights of mice with CT-26 xenograft tumors. (C) Growth curves for HCT116 xenograft tumors. (D) Body weights of mice with HCT116 xenograft tumors. The symbols *, # and $ on the top of the black line are P<0.05 for fisetin, radiation and combined treatment vs. the untreated control, respectively; the symbols * and # beneath the red lines are P<0.05 for fisetin and radiation treatment alone vs. the combined treatment, respectively.

Effect of fisetin on p53 and securin expression in human colorectal cancer cells. (A) Western blots detecting the expression of p53 and securin in wild-type, p53-null and securin-null HCT116 cells, and p53 mutant HT-29 cells, following treatment with different concentrations of fisetin. (B) Quantification of western blots. *P<0.05, **P<0.0005 and ***P<0.0001 vs. 0 µM fisetin.

Effect of fisetin and radiation combination treatment on the growth of securin-null HCT116 xenograft tumors in vivo. (A) Cell growth curves of HCT116WT cells and HCT116securin-/− cells. The cell number of each time point was compared. *P<0.05 vs. the same time point in the HCT116securin-/− cells. (B) Growth curves of HCT116securin-/− xenograft tumors following treatment with fisetin, radiation, or fisetin and radiation combined (n=3 per group). (C) Body weights of mice with HCT116securin-/− xenograft tumors.